# Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

> **NCT06608641** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jina Pharmaceuticals Inc.** · enrollment: 490 (estimated)

## Conditions studied

- Bipolar 1 Disorder

## Interventions

- **DRUG:** Endoxifen enteric-coated tablet (8 mg)
- **DRUG:** Placebo Tablets

## Key facts

- **NCT ID:** NCT06608641
- **Lead sponsor:** Jina Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-19
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 490 (ESTIMATED)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608641, "Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06608641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*